Katsuaki Maehara: Uncommon EGFR Mutations and the variability in therapeutic efficacy

Katsuaki Maehara, Director of Medical Education Colleagues shared a post on X:

“Uncommon EGFR mutations

The purpose of this review is written to synthesize findings from recent clinical trials focused on Uncommon EGFR mutations and to outline the variability in therapeutic efficacy of these TKIs based on specific genetic mutations.”

For patients with L861Q alone, osimertinib tends to exhibit superior activity compared to afatinib. Conversely, in patients with G719X or S768I mutations, afatinib demonstrates a higher ORR and longer PFS than osimertinib. But S768I is less effective than other mutations.

Additionally, osimertinib displays prolonged PFS in patients with both uncommon and common compound EGFR mutations compared to afatinib.

‘From Rarity to Reality: Osimertinib’s Promising Horizon in Treating Uncommon EGFR Mutations in Non–Small Cell Lung Cancer‘

Authors: Akito Fukuda Yusuke Okuma

Source: Katsuaki Maehara/X